NO20053947L - Forbedrede antitumorale behandlinger. - Google Patents

Forbedrede antitumorale behandlinger.

Info

Publication number
NO20053947L
NO20053947L NO20053947A NO20053947A NO20053947L NO 20053947 L NO20053947 L NO 20053947L NO 20053947 A NO20053947 A NO 20053947A NO 20053947 A NO20053947 A NO 20053947A NO 20053947 L NO20053947 L NO 20053947L
Authority
NO
Norway
Prior art keywords
improved antitumoral
antitumoral treatments
treatments
improved
treatment
Prior art date
Application number
NO20053947A
Other languages
English (en)
Other versions
NO20053947D0 (no
Inventor
Jose Jimeno
Debabrata Barnejee
Joseph R Bertino
Saydam Guray
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of NO20053947D0 publication Critical patent/NO20053947D0/no
Publication of NO20053947L publication Critical patent/NO20053947L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15Depsipeptides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Sammendrag Aplidin og aplidinanaloger kan benyttes for behandling av cancer, særlig for behandling av leukemier og lymfomer, og særlig ved kombinasjonsterapi.
NO20053947A 2003-03-12 2005-08-24 Forbedrede antitumorale behandlinger. NO20053947L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45412503P 2003-03-12 2003-03-12
PCT/US2004/007606 WO2004080421A2 (en) 2003-03-12 2004-03-12 Improved antitumoral treatments

Publications (2)

Publication Number Publication Date
NO20053947D0 NO20053947D0 (no) 2005-08-24
NO20053947L true NO20053947L (no) 2005-12-07

Family

ID=32990868

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053947A NO20053947L (no) 2003-03-12 2005-08-24 Forbedrede antitumorale behandlinger.

Country Status (13)

Country Link
US (2) US7576188B2 (no)
EP (1) EP1620117A4 (no)
JP (1) JP2006519848A (no)
KR (1) KR20060002778A (no)
CN (3) CN101579520A (no)
AU (1) AU2004220451B2 (no)
CA (1) CA2516572A1 (no)
MX (1) MXPA05009741A (no)
NO (1) NO20053947L (no)
NZ (1) NZ541634A (no)
RU (1) RU2341283C2 (no)
UA (2) UA83022C2 (no)
WO (1) WO2004080421A2 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
PL200922B1 (pl) * 1999-11-15 2009-02-27 Pharma Mar Sa Zastosowanie aplidyny do wytwarzania kompozycji farmaceutycznej
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
ATE299028T1 (de) 2000-10-12 2005-07-15 Pharma Mar Sa Behandlung von krebserkrankungen mit aplidin in kombination mit carnitin oder acetylcarnitin
ES2312979T3 (es) 2003-03-12 2009-03-01 Dana-Farber Cancer Institute, Inc. Aplidina para el tratamiento de mieloma multiple.
CN101579520A (zh) * 2003-03-12 2009-11-18 达纳-法伯癌症协会有限公司 用于多发性骨髓瘤的治疗的aplidine
WO2007101235A2 (en) * 2006-02-28 2007-09-07 Pharma Mar, S.A. Improved antitumoral treatments
ITMI20070817A1 (it) * 2007-04-19 2008-10-20 Farmacetika Ltd Composizione farmaceutica comprendente l-carnitina ed un agente antagonista dei recettori adenosinici di membrana, loro derivati e/o sali farmaceuticamente accettabili, e uso degli stessi nella preparazione di farmaci con effetto non tossico di inibi
WO2008135793A1 (en) * 2007-05-04 2008-11-13 Pharma Mar S.A. Combination of aplidine and carboplatin in anticancer treatments
US20100240595A1 (en) * 2007-10-19 2010-09-23 Pharma Mar ,S.A. Improved Antitumoral Treatments
EP2262523A1 (en) * 2008-03-07 2010-12-22 Pharma Mar S.A. Improved anticancer treatments
WO2010029158A1 (en) * 2008-09-12 2010-03-18 Pharma Mar, S.A. Aplidine in the treatment of chronic myeloproliferative disorders
CN104706599B (zh) * 2013-12-11 2020-10-02 中国海洋大学 一种携带膜海鞘素化合物的冻干粉针剂
KR102511028B1 (ko) 2016-03-15 2023-03-16 오리존 지노믹스 에스.에이. 혈액 악성 종양의 치료를 위한 lsd1 억제제의 조합물
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
EP0220453B1 (de) * 1985-09-20 1992-04-15 Cernitin S.A. Verwendung von Pflanzenpollenextrakten zur Herstellung von das Wachstum von Tumorzellen hemmenden pharmazeutischen Präparaten und Verfahren zu ihrer Herstellung
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
US5018188A (en) 1989-12-20 1991-05-21 Motorola, Inc. Microphone-controller with multifunction, single conductor
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5482726A (en) * 1992-07-14 1996-01-09 Us Harvest Technologies Corporation Method for reducing contamination of shellfish
US5580871A (en) 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
ES2135359T3 (es) 1996-07-03 2002-05-16 Paxton C G Ltd Recipientes.
PT956033E (pt) 1996-10-24 2003-10-31 Univ Illinois SíNTESE TOTAL DE ANALOGOS AMINO HIP DE DIDEMNINA A
JP2001503746A (ja) 1996-10-24 2001-03-21 ザ・ボード・オブ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・イリノイ ジデムニン類似体の半合成法
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
JP4327260B2 (ja) * 1997-05-07 2009-09-09 フアルマ・マル・エセ・ア L型カルシウムチャンネルエンハンサーとしてのアプリジン
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
GB9821975D0 (en) 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
PL200922B1 (pl) * 1999-11-15 2009-02-27 Pharma Mar Sa Zastosowanie aplidyny do wytwarzania kompozycji farmaceutycznej
SE9904175D0 (sv) 1999-11-18 1999-11-18 Pharmacia & Upjohn Diag Ab Assay device and use thereof
NZ521844A (en) 2000-04-07 2004-07-30 Univ Pennsylvania Tamandarin and didemnin analogs having deoxo-proline residue or dehydro-proline residue and methods of making and use thereof
AU6836301A (en) * 2000-06-20 2002-01-02 Idec Pharma Corp Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
ATE299028T1 (de) * 2000-10-12 2005-07-15 Pharma Mar Sa Behandlung von krebserkrankungen mit aplidin in kombination mit carnitin oder acetylcarnitin
AU9402401A (en) 2000-10-12 2002-04-22 Pharma Mar Sa Treatment of cancers
WO2002058688A1 (de) * 2001-01-24 2002-08-01 Mestex Ag Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen
ATA13422001A (de) 2001-08-23 2003-09-15 Plasser Bahnbaumasch Franz Maschine zur bearbeitung einer gleisbettung
CA2462642A1 (en) 2001-10-19 2003-04-24 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
ES2312979T3 (es) 2003-03-12 2009-03-01 Dana-Farber Cancer Institute, Inc. Aplidina para el tratamiento de mieloma multiple.
CN101579520A (zh) 2003-03-12 2009-11-18 达纳-法伯癌症协会有限公司 用于多发性骨髓瘤的治疗的aplidine

Also Published As

Publication number Publication date
KR20060002778A (ko) 2006-01-09
CN101579520A (zh) 2009-11-18
EP1620117A2 (en) 2006-02-01
AU2004220451B2 (en) 2010-01-21
MXPA05009741A (es) 2005-11-16
US7576188B2 (en) 2009-08-18
NO20053947D0 (no) 2005-08-24
NZ541634A (en) 2008-08-29
CN1753684A (zh) 2006-03-29
WO2004080421A2 (en) 2004-09-23
UA82089C2 (uk) 2008-03-11
RU2341283C2 (ru) 2008-12-20
US20090227490A1 (en) 2009-09-10
EP1620117A4 (en) 2009-07-29
RU2005126819A (ru) 2006-01-20
UA83022C2 (uk) 2008-06-10
CN1761480A (zh) 2006-04-19
US20060178298A1 (en) 2006-08-10
CA2516572A1 (en) 2004-09-23
CN100409895C (zh) 2008-08-13
WO2004080421A3 (en) 2005-06-09
AU2004220451A1 (en) 2004-09-23
CN1761480B (zh) 2012-09-26
JP2006519848A (ja) 2006-08-31

Similar Documents

Publication Publication Date Title
NO20053947L (no) Forbedrede antitumorale behandlinger.
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
WO2006015263A3 (en) Lonidamine analogs
PT1682126E (pt) Benzazois substituídos e sua utilização como inibidores da quinase raf
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
DE60327103D1 (de) Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer
WO2007047608A3 (en) Fibrin targeted therapeutics
NO20054668L (no) Aplidin for multippelt myelom-behandling
WO2004012662A3 (en) Improved treatment of cancer with glutamine
WO2002076548A3 (en) Methods and apparatus for treating diseased tissue
HK1057336A1 (en) Pharmaceutical solutions of modafinil compounds
ATE442188T1 (de) Bestrahlungseinrichtung
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
WO2005060960A3 (en) Use of histamine to treat bone disease
HK1079116A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
DE60326931D1 (de) In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
ECSP013869A (es) Tratamiento del dolor
WO2006069217A3 (en) Small molecule cyclin d1 ablative agents
TW200640484A (en) Treatment of brain tissue damage
MXPA04000418A (es) Tratamiento de dolor cronico con 3-heterocicloxi- y -cicloalquiloxi-3-fenilpropanaminas.
MXPA05002477A (es) Asialo-interferones y el tratamiento de cancer de higado.
AU2003229876A8 (en) Tumour associated antigens
AR051035A1 (es) Uso de epotilonas en el tratamiento de metastasis en hueso
MY136408A (en) Active substance combinations and therapies for treating abuse of alcohol
UA70017A (en) Method for conservative treatment of chronic tonsillitis in adults

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application